Pfizer shares sink in German trading
(AP)


<p><a href="http://us.rd.yahoo.com/dailynews/rss/health/*http://news.yahoo.com/s/ap/20061204/ap_on_he_me/pfizer_cholesterol_drug"><img src="http://d.yimg.com/us.yimg.com/p/ap/20061203/capt.afe7fcfa4c2544a5bfcd5f7080917817.pfizer_cholesterol_drug_ny117.jpg?x=130&y=87&sig=2IWEMZqhc7IRjVhrB.ofDQ--" align="left" height="87" width="130" alt="Jeff Kindler, CEO of Pfizer, speaks at the opening of their R&D Analyst meeting presentations in Groton Conn., in this Thursday, Nov. 30, 2006 file photo. Pfizer Inc. will likely slash staff and accelerate merger and licensing deals as the pressure on it to improve its financial performance intensified after the weekend's announcement that the company ended development of a key drug, analysts said. (AP Photo/Fred Beckham)" border="0" /></a>AP - Shares of Pfizer Inc., the world's largest drugmaker, sank Monday in German trading on news that the company has halted development of a key new cholesterol treatment.</p><br clear="all"/>